Project Grant R21AI199182
Award Date 9/2/26
Completion Date 8/31/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $411,078 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel antifungal compounds from symbiotic bacteria capable of combating drug-resistant Candida auris. The research exploits symbiotic bacteria—organisms that co-exist with and benefit their eukaryotic hosts—as a source of antifungal molecules with low mammalian toxicity. The...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant K99AI201933) to define the fungal and host determinants of Candida auris skin colonization. The research addresses mechanisms by which Candida auris, an emerging multidrug-resistant fungal pathogen classified by the...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $412,324 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether echinocandin susceptibility can be restored to cross-resistant Candida strains by targeting genes that antagonize FKS gene products. The research uses genome-wide transposon sequencing screens in two cross-resistant derivatives of Candida glabrata to identify candidate genes and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,383 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms and dynamics of genome plasticity in antifungal-resistant Candida species. The project addresses the molecular drivers of antifungal resistance in Candida albicans, Candida glabrata, and Candida auris through examination of large DNA amplification events, aneuploid...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $245,233 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize a previously unknown family of pore-forming toxins in non-albicans Candida species. The project clones, expresses, and tests the cytotoxic activity of aerolysin-like toxin (KTO) genes detected in Candida species against a broad panel of potential fungal competitors and...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $159,560 in project grant funding on October 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the determinants of fluconazole resistance evolvability in Candida auris, an emerging multidrug-resistant fungal pathogen. The research investigates the biological mechanisms underlying the high frequency of acquired resistance...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $437,250 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize genetic and phenotypic diversity of Candida parapsilosis populations in bloodstream infections and to identify genetic variants and genes associated with echinocandin heteroresistance or tolerance. C. parapsilosis is the second or third most common cause of candidemia and a...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut $251,062 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antifolate compounds with broad-spectrum antifungal activity targeting invasive fungal infections. The funded research addresses unmet clinical needs in treating opportunistic and emerging fungal pathogens, including Candida auris, Candida albicans, Candida glabrata, Cryptococcus neoformans,...